Progress in cancer research: characterisation of a new PPAR Beta/Delta antagonist, GSK3787, with Roche's xCELLigence system

05.08.2010 , Biotechnik, Roche Diagnostics GmbH

The peroxisome proliferatoractivate­d receptors (PPAR Alpha, Beta/Delta and Gamma) are nuclear receptors that modulate transcription of regulatory pathways involved...

zur Pressemeldung